Skip to main content
Profound Medical Corp. logo

Profound Medical Corp. — Investor Relations & Filings

Ticker · PROF TSX Manufacturing
Open in API
Filings indexed 659 across all filing types
Latest filing 2023-09-21 Investor Presentation
Country CA Canada
Listing TSX PROF

About Profound Medical Corp.

https://profoundmedical.com/

Profound Medical Corp. is a commercial-stage medical technology company specializing in incision-free ablative therapies. Its core product is TULSA-PRO®, a therapeutic platform designed for the treatment of localized prostate cancer, radiorecurrent prostate cancer, and benign prostatic hyperplasia (BPH). TULSA-PRO utilizes a robotically controlled, transurethral ultrasound ablation procedure guided by real-time Magnetic Resonance (MR) imaging. This system employs closed-loop temperature feedback to ensure precise and customizable tissue ablation, prioritizing patient safety and minimizing complications. The technology merges MR imaging, thermal ultrasound, and robotics to offer a durable and accurate treatment delivery method.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Investor Presentation Classification · 90% confidence The document is a short announcement (3269 characters) about an upcoming virtual Analyst & Investor Day event hosted by Profound Medical Corp. It describes the event's agenda, including presentations and management updates, and provides logistical details for participation. There is no detailed financial data, no full report, no earnings release, and no regulatory filing content. The document serves as an invitation and informational notice about the event rather than the event materials or a financial report itself. According to the classification rules, such announcements about upcoming investor presentations or events are best classified as Investor Presentation (IP) if they contain the presentation itself, or Report Publication Announcement (RPA) if announcing a report release. However, since this is an announcement of an event (Analyst & Investor Day) and not the presentation materials themselves, it fits best under Investor Presentation (IP) category as it is focused on investor communication and presentations, even though the actual presentation is to be held in the future. Confidence is high due to clear event description and investor focus.
2023-09-21 English
News release - English.pdf
Investor Presentation Classification · 90% confidence The document is a press release announcing that Profound Medical will participate in the 2023 Cantor Global Healthcare Conference and provide a business update presentation. It includes company background information and details about the upcoming presentation date and webcast. There are no financial statements, detailed financial results, or regulatory filings included. The document is short (2596 characters) and serves as an announcement of an investor presentation event rather than the presentation itself or a financial report. Therefore, it fits best under the category of Investor Presentation (IP) announcement, but since it is only announcing the participation and presentation, it is not the presentation itself. However, given the options, the closest classification is Investor Presentation (IP) as it relates to a detailed presentation for investors focusing on financials, strategy, and market position, even though the actual presentation is forthcoming. Confidence is high due to clear context and content.
2023-09-19 English
Other material contract(s).pdf
Board/Management Information Classification · 100% confidence The document is a press release announcing the resignation of a director from the company's board. It contains no financial data, no report or presentation, and no mention of voting results or other regulatory filings. The content focuses solely on management changes at the board level. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and does not indicate it is an announcement of a report or certification, so it is not RPA or RNS.
2023-09-07 English
Consent letter of issuer's legal counsel.pdf
Regulatory Filings Classification · 95% confidence The document is a letter from Mintz LLP providing consent related to a Prospectus Supplement dated September 6, 2023, for Profound Medical Corp. It references the Prospectus Supplement and confirms no misrepresentations in the information. The document is short (1855 characters) and is a formal consent letter rather than the Prospectus Supplement itself or a financial report. It is related to a capital raising document (Prospectus Supplement) but is not the actual supplement or a financial report. Therefore, it is best classified as a Regulatory Filing (RNS), which covers miscellaneous regulatory announcements and compliance documents that do not fit other categories.
2023-09-07 English
Consent letter(s) of other legal counsel.pdf
Regulatory Filings Classification · 95% confidence The document is a letter from a law firm (Osler, Hoskin & Harcourt LLP) addressed to multiple Canadian securities commissions. It references a prospectus supplement dated September 6, 2023, related to a short form base shelf prospectus dated March 23, 2022. The letter provides consent to the use of the firm's opinion in the supplement and states that they have no reason to believe there are misrepresentations in the supplement. The document is short (1955 characters) and serves as a legal consent and opinion letter related to a prospectus filing, not the prospectus or supplement itself. It does not contain financial statements or detailed financial data. This type of document is best classified as a Regulatory Filing (RNS), as it is a legal attestation related to a regulatory filing rather than a full report or announcement of financial results.
2023-09-07 English
Auditors' consent letter.pdf
Regulatory Filings Classification · 95% confidence The document is a letter from PricewaterhouseCoopers LLP addressed to multiple Canadian securities commissions. It refers to a prospectus supplement and consents to the use of their audit report dated March 7, 2023, on the consolidated financial statements of Profound Medical Corp. for the years ended December 31, 2022 and 2021. The letter explicitly states it is a consent to use the auditor's report in an offering document and clarifies that it is not an audit or review of the prospectus itself. The document length is short (2629 characters) and it does not contain actual financial statements or substantive financial data, only a consent letter. According to the CERTIFICATION RULE and MENU VS MEAL RULE, this type of document is classified as a Regulatory Filing (RNS) because it is an auditor's consent letter related to a prospectus and does not contain the full audit report or financial statements themselves.
2023-09-07 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.